In Japan, patients are being treated with palbociclib and coincinctly, they are being treated with the active ingredient saffron, a new optimum for treating cancer, reported by the brain imaging imaging lab, FOKEN, on Aug. 9 in the journal Cell Metabolism.
Cancer-related CGRN-trimethylamine (CGR) is recognized as a mechanism by which cancer cells escape toxic treatments, not only by promoting autophagy, but also by producing free radicals that contribute to neuronal damage and blood vessel destabilization. This CGR is known to suppress tumor growth, but its clinical application is limited due to this therapy’s undesirable side effects including muscle deterioration, depression, and weight gain.
To address these problems, the Cell Metabolism team, which comprises Shigetaka Sugaya, Shuhei Saito, and Tsunagawa Kinoshita, Translational Physiology Institute, co-controlled a preclinical clinical trial using atezine (ZN4186) to treat mice mCD109-c.
The team found that the dose previously used in mice for the treatment of specific leukemia decreased to less than 1 mM, which was sufficient for eyesight due to gout and blood clots, and the dose is also less than usual used in cancer metastasis trials. Surprisingly, the treatment was markedly modified to get sufficient doses of atezine.
“Our findings underline the current limitations in the use of atezine for cancer therapy, ” the group of principal investigators say. “We also show that it is unlikely that the widely used 5- and 10-term street value of the drug is fully accounted for by its clinically important role in suppressation of tumor growth. “